UNSPSC 51381902: Fenpipalone

This classification denotes a nonsteroidal antiinflammatory drug with the molecular formula C17H22N2O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 6TVC31DEDE, chemically known as 5-(2-(3,6-dihydro-4-phenyl-1(2h)-pyridyl)ethyl)-3-methyl-2-oxazolidinone but generally known as fenpipalone, which bears US NIH Compound Identifier 30822. European Medicines Agency schedules Fenpipalone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07587MIG.

UNSPSC 51381902 Fenpipalone is a Commodity code that covers pharmaceutical products and drug-related supplies procured by state and local health agencies, though recent state and local opportunities tagged to this code show minimal direct activity under the fenpipalone nomenclature itself. Instead, the code appears in solicitations for broader pharmaceutical procurement — including naloxone systems, generic multi-source pharmaceuticals, and over-the-counter products — as well as exploratory requests for information on direct-to-manufacturer prescription programs. State and local issuing bodies soliciting under this code include county health departments, state health and human services agencies, and cooperative purchasing alliances representing multiple state and local government entities. The actual work involves sourcing, qualifying, and procuring pharmaceutical and related health products for distribution to community health facilities, with vendors managing logistics, compliance with Good Manufacturing Practices and Drug Supply Chain Security Act requirements, and submission of detailed product and pricing data.

Recent activity spans Florida, Texas, and Minnesota through cooperative purchasing. Seminole County, Florida issued IFB 60459723LAS (posted June 30, 2026; response deadline July 26, 2023) to procure 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to its Community Health Building, requiring vendors to include all shipping costs and comply with drug-free workplace and E-Verify certification. The Texas Health and Human Services Commission issued RFI HHS0017013 (posted April 3, 2026; response deadline April 3, 2026) to gather vendor capabilities for a Therapeutic Pharmacy Initiative direct-to-manufacturer prescription program, seeking information on direct contracting capacity outside traditional pharmacy benefit manager and group purchasing organization channels. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued RFP S1070000015802 (posted January 20, 2026; response deadline March 26, 2026) for generic multi-source pharmaceuticals and OTC products distributed through three authorized wholesalers, with awarded contracts effective July 1, 2026, and pricing evaluation weighted 75 percent on competitiveness.